LIQUIDIA CORPORATION (LQDA) Operating Margin
- Operating margin · 12 months: Value 37.39%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 37.39% | Operating income / revenue. Period ending 2026-06-30. $168.57M ÷ $450.91M × 100 ≈ 37.39% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 168.57M USD | Operating Income (Loss) |
| Revenue | 450.91M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 56.04M USD | Research and Development Expense |
| Selling, general and administration | 192.66M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $168.57M | $450.91M | (m) | $56.04M | $192.66M | 37.39% |
| 2026-03-31 | $45.55M | $288.06M | (m) | $44.88M | $174.05M | 15.81% |
| 2025-12-31 | $-51.38M | $158.32M | (m) | $39.28M | $157.18M | -32.45% |
| 2025-09-30 | $-107.27M | $69.22M | (m) | $38.81M | (m) | -154.98% |
| 2025-06-30 | $-138.23M | $19.32M | (m) | $41.35M | (m) | -715.38% |
| 2025-03-31 | $-127.92M | $14.14M | $5.93M | $44.75M | (m) | -904.40% |
| 2024-12-31 | $-121.29M | $14.00M | $5.88M | $47.84M | (m) | -866.63% |
| 2024-09-30 | $-111.62M | $15.61M | $5.52M | $44.20M | (m) | -715.07% |
| 2024-06-30 | $-97.33M | $14.84M | $4.52M | $39.75M | (m) | -655.83% |
| 2024-03-31 | $-92.95M | $15.97M | $3.70M | $48.02M | (m) | -582.16% |
| 2023-12-31 | $-73.38M | $17.49M | $2.89M | $43.24M | (m) | -419.62% |
| 2023-09-30 | $-53.45M | $18.32M | $2.59M | $35.39M | (m) | -291.78% |
| 2023-06-30 | $-47.38M | $17.80M | $2.76M | $32.46M | (m) | -266.15% |
| 2023-03-31 | $-33.53M | $16.94M | $2.82M | $19.98M | (m) | -197.98% |
| 2022-12-31 | $-38.77M | $15.94M | $2.86M | $19.43M | (m) | -243.30% |
| 2022-09-30 | $-43.64M | $13.79M | $2.89M | $19.84M | (m) | -316.42% |
| 2022-06-30 | $-41.89M | $13.80M | $3.04M | $19.81M | (m) | -303.44% |
| 2022-03-31 | $-39.27M | $13.26M | $3.02M | $19.19M | (m) | -296.11% |
| 2021-12-31 | $-33.80M | $12.85M | $3.02M | $20.52M | (m) | -262.94% |
| 2021-09-30 | $-38.35M | $10.38M | (m) | $20.38M | (m) | -369.52% |
| 2021-06-30 | $-46.08M | $7.20M | (m) | $23.56M | (m) | -640.08% |
| 2021-03-31 | $-53.44M | $3.82M | (m) | $27.45M | (m) | -1397.87% |
| 2020-12-31 | $-59.09M | $739.63K | (m) | $32.22M | (m) | -7989.03% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-46.82M | $8.07M | (m) | $40.49M | (m) | -580.07% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |